YUCAIPA, Calif., May 28, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT) is an established medical device manufacturer with an emerging new medical product line targeting the rapidly growing $8 billion global respiratory market. The company recently announced that the pre-recorded interview from Wednesday with CEO, Scott Sand, will be aired again on The Money Channel's American Scene Radio with host Steve Crowley today at 11:24 AM Eastern Daylight Time.
Sand will discuss the new IngenCare product for the $2 trillion drug therapy market expected to be released in August. With the provisional patent filed and production expected in June, the product uses polymer-crystal technology to keep drugs, such as insulin, cool and dry for more than 12 hours while on the go. It is compact, durable and temperature resistant. In addition, Sand will discuss the newest patent on a cannula that will change various colors depending upon flow rate. This new innovative material is embedded into the actual PVC tubing and changes color with various flow rates. "This new product will literally corner the market and complement Ingen's existing Smart Nasal Cannula," stated Scott Sand.
View article: http://respiratorysleepmanagement.com/articles/2010/05/14/medtrade-features-respiratory-sleep-innovations.aspx
"Ingen stands at a key reflex point in its history after having developed a unique solution to a growing problem in the $500 million per year oxygen cannula market," stated Scott Sand, CEO. Ingen recently expanded into 300 VA hospitals in the U.S. through its contract with KGMA, which could quickly ramp up sales to a large patient population, while validating its products in the market.
Ingen recently completed its ISO 13485I, which will help it expand into international markets where it already has a substantial backlog of orders. "Our products can help cut costs for oxygen providers like Lincare Holdings Inc. (LNCR) and Cardinal Health, Inc. (CAH) among other companies, and address a rapidly growing $8 billion global respiratory market facing a COPD epidemic," stated Thomas J. Neavitt, Chief Financial Officer.
http://www.smartnasalcannula.com/
http://www.ingenpulseoximeter.com/
About Ingen:
Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.